These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 8683995

  • 21. Protein kinase C activation modulates pro- and anti-apoptotic signaling pathways.
    Meinhardt G, Roth J, Totok G.
    Eur J Cell Biol; 2000 Nov; 79(11):824-33. PubMed ID: 11139146
    [Abstract] [Full Text] [Related]

  • 22. Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
    Grant S, Turner AJ, Bartimole TM, Nelms PA, Joe VC, Jarvis WD.
    Oncol Res; 1994 Nov; 6(2):87-99. PubMed ID: 7949469
    [Abstract] [Full Text] [Related]

  • 23. Bryostatin 1 increases 1-beta-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L).
    Wang Z, Wang S, Dai Y, Grant S.
    J Pharmacol Exp Ther; 2002 May; 301(2):568-77. PubMed ID: 11961058
    [Abstract] [Full Text] [Related]

  • 24. Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis.
    Bartimole TM, Vrana JA, Freemerman AJ, Jarvis WD, Reed JC, Boise LH, Grant S.
    Cell Death Differ; 1997 May; 4(4):294-303. PubMed ID: 16465244
    [Abstract] [Full Text] [Related]

  • 25. Modulation of ara-C induced apoptosis in leukemia by the PKC activator bryostatin 1.
    Grant S.
    Front Biosci; 1997 Jun 01; 2():d242-52. PubMed ID: 9195893
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. In vivo synergistic effect of the immunomodulator AS101 and the PKC inducer bryostatin.
    Kalechman Y, Albeck M, Sredni B.
    Cell Immunol; 1992 Aug 01; 143(1):143-53. PubMed ID: 1623562
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67).
    Grant S, Freemerman AJ, Birrer MJ, Martin HA, Turner AJ, Szabo E, Chelliah J, Jarvis WD.
    Cell Growth Differ; 1996 May 01; 7(5):603-13. PubMed ID: 8732670
    [Abstract] [Full Text] [Related]

  • 34. Human THP-1 monocytic leukemic cells induced to undergo monocytic differentiation by bryostatin 1 are refractory to proteasome inhibitor-induced apoptosis.
    Chen C, Lin H, Karanes C, Pettit GR, Chen BD.
    Cancer Res; 2000 Aug 15; 60(16):4377-85. PubMed ID: 10969781
    [Abstract] [Full Text] [Related]

  • 35. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2.
    Mohammad RM, Beck FW, Katato K, Hamdy N, Wall N, Al-Katib A.
    Biol Chem; 1998 Oct 15; 379(10):1253-61. PubMed ID: 9820586
    [Abstract] [Full Text] [Related]

  • 36. The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3.
    van der Hem KG, Dräger AM, Huijgens PC, Tol C, Devillé W, Langenhuijsen MM.
    Leukemia; 1994 Feb 15; 8(2):266-73. PubMed ID: 7508534
    [Abstract] [Full Text] [Related]

  • 37. Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.
    Wang Z, Van Tuyle G, Conrad D, Fisher PB, Dent P, Grant S.
    Cancer Res; 1999 Mar 15; 59(6):1259-67. PubMed ID: 10096557
    [Abstract] [Full Text] [Related]

  • 38. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C.
    Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S.
    Cancer Res; 1994 Apr 01; 54(7):1707-14. PubMed ID: 7511048
    [Abstract] [Full Text] [Related]

  • 39. Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration.
    Bear HD, McFadden AW, Kostuchenko PJ, Lipshy KA, Hamad GG, Turner AJ, Roberts JD, Carr M, Carr S, Grant S.
    Anticancer Drugs; 1996 May 01; 7(3):299-306. PubMed ID: 8792004
    [Abstract] [Full Text] [Related]

  • 40. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity.
    Wang H, Mohammad RM, Werdell J, Shekhar PV.
    Int J Mol Med; 1998 Jun 01; 1(6):915-23. PubMed ID: 9852625
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.